| Business Summary | | AEterna
Laboratories
Inc.
is
a
biopharmaceutical
company
focused
on
the
development
of
new
therapeutics
for
unmet
medical
needs,
principally
cancer.
AEterna's
lead
compound,
AE-941,
is
an
angiogenesis
inhibitor
in
clinical
trials
in
three
major
indications:
oncology,
dermatology
and
ophthalmology.
AE-941/Neovastat
is
entering
its
pivotal
stage
of
development
with,
among
others,
a
Phase
III
trial
for
the
treatment
of
lung
cancer
in
collaboration
with
the
U.S.
National
Cancer
Institute
(NCI).
AEterna's
strategy
is
to
build
a
portfolio
of
complementary
technologies
that
will
leverage
its
resources
and
expertise
in
drug
development
and
target
diseases
with
significant
market
potential.
AEterna,
through
its
subsidiary
Atrium
Biotechnologies,
is
also
involved
in
the
development
of
active
ingredients
for
use
in
cosmetics
and
nutritional
supplements. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | AELA
is
a
Canadian
biopharmaceutical
company.
The
Company's
lead
product,
Neovastat,
is
the
focus
of
a
number
of
clinical
trials
for
the
treatment
of
lung
and
kidney
cancer.
For
the
six
months
ended
6/30/01,
revenues
rose
35%
to
C$5.4
million.
Net
income
totaled
C$4.3
million
vs.
a
loss
of
C$3.8
million.
Revenues
reflect
increased
sales
in
the
U.S.
and
Asia
and
a
benefit
from
an
acquisition.
Net
income
reflects
an
increase
in
research
and
development
tax
credits. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Eric Dupont, Ph.D. | Chairman,
Pres, CEO | Gilles Gagnon | COO,
VP | Luc Dupont | Exec.
VP, Director | Dennis Turpin | VP,
CFO | Claude Vadboncoeur | VP-
Legal Affairs, Sec. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|